Cigna Pledges Transparency (Without Using Any Data), Centene Swings to a Billion-Dollar Profit on Shrinking Enrollment, and Addyi Doubles Sales via Social Media

Hey all, 

Happy Thursday! Welcome to the newsletter where we decode the distance between what healthcare companies say in their press releases and what they actually do to your bank account. It’s a masterclass in creative writing: Cigna is currently rebranding "gatekeeping" as "transparency" with a glossy PDF that omits actual denial rates, while Centene manages to spin a $1.5 billion profit as a victory for "modernization" even as two million people lose their ACA coverage. Apparently, the industry has perfected the "pharm-to-table" model where they hike list prices into the stratosphere just to sell you a "discounted" $149 bypass route, proving that "innovation" is usually just a pricing or distribution model tweak.

Enjoy the rundown!

Jacob Brody (Co-Founder & CEO, ZorroRX)

[HEALTH CARE un-covered] Cigna's "Transparency Report" as a Strategic PR Tactic

Wendell Potter argues that Cigna’s new "Customer Transparency Report" and recent industry-wide pledges are calculated PR maneuvers intended to appease public outrage and preempt genuine federal regulation. The report lacks granular data on claim denial rates and specific services removed from prior authorization, suggesting that the industry is merely streamlining low-cost requests while maintaining opaque systems for expensive, life-saving care. In the high-stakes world of medical gatekeeping, it turns out that "transparency" is just a fancy industry term for a glossy PDF that tells you absolutely everything except for the things you actually need to know.

Full Article

(Fierce Healthcare) Centene swings to $1.5B profit as Medicaid business improves even as ACA membership falls by 2 million

Centene Corporation reported a $1.5 billion profit for the first quarter of 2026, driven primarily by aggressive margin recovery in its Medicaid segment and a surprisingly strong performance in Medicare. While the company celebrated hitting its financial targets, its ACA Marketplace enrollment plummeted by 2 million members following the expiration of federal premium tax credits. This financial rebound underscores the industry’s shift toward "standardizing processes" and "network optimization" to wring profit out of medical cost trends even as the individual market shrinks. It’s heartening to see that while 2 million people were discovering they could no longer afford their insurance, Centene was busy discovering a billion-dollar "silver lining" through the magic of corporate modernization.

Full Article

[Apex] The Commercial Evolution of Addyi and the Rise of Pharm-to-Table Marketing

Addyi, an 11-year-old female libido drug, has seen its monthly prescriptions double in the last six months by combining an expanded indication for post-menopausal women with a dual-pricing strategy that pairs a massive list price hike with a $149 cash-pay telehealth option. This surge was further fueled by an aggressive direct-to-patient social media push and partnerships with telehealth providers, marking a significant departure from traditional pharmaceutical distribution. It’s a bold new world where you can bypass the pesky medical establishment entirely, provided you have a decent Wi-Fi connection and a credit card that doesn't mind a little "pharm-to-table" disruption of your bank account.

Full Article